| 免疫检查点抑制剂在复发/转移性鼻咽癌中的应用 |
| |
| 引用本文： | 高洋,孙昭,白春梅. 免疫检查点抑制剂在复发/转移性鼻咽癌中的应用[J]. 协和医学杂志, 2020, 11(5): 626-630. DOI: 10.3969/j.issn.1674-9081.2020.05.021 |
| |
| 作者姓名： | 高洋 孙昭 白春梅 |
| |
| 作者单位： | 中国医学科学院 北京协和医学院 北京协和医院肿瘤内科，北京 100730 |
| |
| 基金项目： | 中国医学科学院医学与健康科技创新工程2016-12M-1-001 |
| |
| 摘 要： | 鼻咽癌多与EB病毒感染相关，早期患者及时治疗后预后良好，但复发/转移性鼻咽癌治疗方式有限，预后不佳。近年来，免疫治疗在复发/转移性鼻咽癌中的研究十分广泛，其中免疫检查点抑制剂药物具有较好的疗效和良好的耐受性，引起临床广泛关注。程序性死亡受体-配体1(programmed death-ligand 1, PD-L1)表达状态、肿瘤突变负荷、循环EB病毒-DNA水平可能成为免疫检查点抑制剂疗效预测的生物标志物。本文将对免疫检查点抑制剂及其在复发/转移性鼻咽癌中的应用进行综述。
|
| 关 键 词： | 鼻咽癌 免疫检查点抑制剂 生物标志物 |
| 收稿时间： | 2020-01-10 |
Application of Immune-checkpoint Inhibitors in Recurrent/Metastatic Nasopharyngeal Carcinoma |
| |
| Affiliation: | Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China |
| |
| Abstract: | Nasopharyngeal carcinoma is mainly associated with Epstein-Barr virus(EBV) infection. The treatment of early nasopharyngeal carcinoma has a good prognosis, but the treatment options for recurrent/metastatic nasopharyngeal carcinoma are limited and the prognosis is poor. In recent years, there have been extensive studies on immunotherapy in advanced nasopharyngeal carcinoma, among which immune-checkpoint inhibitors are effective and causing clinical concern. Programmed death-ligand 1 expression status, tumor mutation burden and circulating EBV-DNA level may be biomarkers for predicting the efficacy of immune-checkpoint inhibitors. The applications of immune-checkpoint inhibitors in recurrent/metastatic nasopharyngeal carcinoma will be reviewed in this article. |
| |
| Keywords: | |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《协和医学杂志》浏览原始摘要信息 |
|
点击此处可从《协和医学杂志》下载免费的PDF全文 |
